title: Clinical effects of clarithromycin on persistent inflammation following Haemophilus influenzae-positive acute otitis media.
abstract: CONCLUSIONS
  Additional treatment with clarithromycin (CAM) reduced persistent middle ear inflammation after acute otitis media (AOM) caused by Haemophilus influenzae in children. CAM is a treatment option for persistent inflammation following AOM and to prevent continuing otitis media with effusion.
  
  
  OBJECTIVE
  We conducted a clinical study to evaluate a new method of treatment for persistent inflammation after AOM in children.
  
  
  METHODS
  H. influenzae-infected children with AOM were treated acutely with antimicrobial agents, after which those still demonstrating effusion of the middle ear cavity received additional treatment with carbocysteine (S-CMC) alone or S-CMC combined with clarithromycin (CAM) for 1 week. The two regimens were compared in terms of clinical effects.
  
  
  RESULTS
  After the initial acute treatment, many patients still showed abnormal otoscopic findings. At the completion of additional treatment, there were no significant differences between the two treatment groups. However, 1 week after completion of additional treatment, the prevalence of a diminished light reflex was significantly lower in the CAM + S-CMC group than in the S-CMC group (p = 0.017). The prevalence of redness of the tympanic membrane also tended to be lower in the combined treatment group than in those receiving a single drug (p = 0.097).
authors: Department of Otolaryngology, Jichi Medical University, Saitama Medical Center , Saitama.
authors: Yukiko
authors: Y
authors: Iino
authors: Naohiro
authors: N
authors: Yoshida
authors: Toshinori
authors: T
authors: Kato
authors: Keiko
authors: K
authors: Kakizaki
authors: Tetsuo
authors: T
authors: Miyazawa
authors: Hiroyuki
authors: H
authors: Kakuta
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D002233:Carbocysteine / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D017291:Clarithromycin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006192:Haemophilus Infections / Q000188:drug therapy*; D006193:Haemophilus influenzae; D006801:Humans; D007223:Infant; D008297:Male; D010033:Otitis Media / Q000188:drug therapy* / Q000382:microbiology; D017211:Treatment Failure
chemical_list: D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D002233:Carbocysteine; D017291:Clarithromycin
keywords: Biofilm; cell invasion; clinical effects